- Data show dose-responsive, non-saturated increases in gastrointestinal consumption of Phe in humans by SYNB1618 - - SYNB1618 Phase 2 study in patients with PKU ongoing with proof-of-concept readout anticipated in 2H 2021 - - Phase 1 study of SYNB1934, an evolved strain of SYNB1618 in the PKU...

- SYNB1934, an evolved strain of SYNB1618, has the potential to provide increased benefit to patients living with PKU - - SYNB1934 Phase 1 Study to evaluate safety, tolerability, and head-to-head comparison of biomarkers of Phe-consumption between SYNB1934 and SYNB1618 - - SYNB1618 Phase 2 Study in...

CAMBRIDGE, Mass. , June 17, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it has entered into a research collaboration agreement with Roche for the discovery of a novel...

- SYNB1618 Phase 2 study in patients with PKU ongoing with readout expected in 2H 2021; SYNB1934 demonstrates 2-fold improvement in activity in multiple pre-clinical models - - SYNB8802 Phase 1 study ongoing; readout from Part B placebo-controlled crossover in patients with Enteric Hyperoxaluria...

- SYNB8802 Phase 1 study in patients with Enteric Hyperoxaluria ongoing; readout from Part B placebo-controlled crossover stage expected 2H 2021 -   Cambridge, Mass. (PR Newswire) June 10, 2021 – Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of...

CAMBRIDGE, Mass. , June 3, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, reminds stockholders that it will hold its 2021 Annual General Meeting of Stockholders on June 10, 2021 at 9:00 am ET ....

CAMBRIDGE, Mass. , May 25, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of...

CAMBRIDGE, Mass. , May 23, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on an investigational program to develop Synthetic Biotic™ medicines for the treatment of...

- Proof of concept studies for co-lead metabolic programs SYNB1618 in PKU and SYNB8802 in Enteric Hyperoxaluria on track for 2H 2021 readouts - - $94.4 million in cash, cash equivalents, and short-term investments as of March 31 plus April financing of $32.6 million (net) enables runway extension...

CAMBRIDGE, Mass. , May 6, 2021 /PRNewswire/ --  Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its first quarter 2021 financial results before the market opens on Thursday,...

CAMBRIDGE, Mass. , April 16, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering...

CAMBRIDGE, Mass. , April 15, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering of its common stock....